Founded by Dr Mark Kotter and Florian Schuster, bit.bio is an award-winning human synthetic biology enterprise.
bit.bio’s mission is coding cells for health.
To do so, we apply the principles of computation to biology.
Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease.
A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies.
To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy.
Collaboration is at the heart of bit.bio. We are empirical, ambitious, trustworthy and driven by a common purpose.
We create codes for cures.
We are driven and ambitious in building a scalable technology platform capable of producing consistent batches of every human cell. We are democratising access to high-quality human cells for research, drug discovery and a new generation of cures.
We innovate discovery and partnerships.
Innovation is at the core of what we do. In addition to our breakthrough technology we harness innovation in our business practices, pricing, and partnerships to protect people and the planet. We are creating new industries and long-term opportunities.
We revolutionise biomanufacturing and biomedical research.
We enable innovators to focus on what they do best, leveraging our cell coding platform to provide the cells. We are uncovering the “operating system of life”, transitioning biology to engineering, sharing genetic resources & knowledge/benefits globally, mobilising enterprise & finance on synthetic biology.
Dr Mark Kotter, Founder CEO